Alvotech Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.12.24	Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 (GlobeNewswire)
13.11.24	Alvotech Reports Financial Results for the First Nine Months of 2024 (GlobeNewswire)
07.11.24	Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 (GlobeNewswire)
04.11.24	European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) (GlobeNewswire)
30.10.24	Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET (GlobeNewswire)
25.10.24	Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 (GlobeNewswire)
22.10.24	Alvotech And Teva Pharmaceuticals Announce Expansion Of SELARSDI's Indications (RTTNews)
22.10.24	Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us (GlobeNewswire)
10.10.24	European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® (GlobeNewswire)
25.09.24	Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® (GlobeNewswire)
26.08.24	Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
15.08.24	Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 (GlobeNewswire)
15.08.24	European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) (GlobeNewswire)
01.08.24	Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET (GlobeNewswire)
22.07.24	STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe (GlobeNewswire)
11.07.24	Alvotech Announces Closing of Private Debt Financing (GlobeNewswire)
02.07.24	Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® (GlobeNewswire)
01.07.24	Alvotech Issues New Shares to Holders of Convertible Bonds (GlobeNewswire)
01.07.24	Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 (GlobeNewswire)
26.06.24	Alvotech Receives Conversion Notices for Majority of Convertible Bonds (GlobeNewswire)
18.06.24	Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe (GlobeNewswire)
11.06.24	Alvotech and STADA add to Strategic Alliance through Denosumab Partnership (GlobeNewswire)
07.06.24	Alvotech Announces Strategic Refinancing Agreement (GlobeNewswire)
29.05.24	Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 (GlobeNewswire)
21.05.24	Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update (GlobeNewswire)
21.05.24	Alvotech Partners Dr. Reddy's To Bring AVT03 Biosimilar To Prolia & Xgeva To U.S., Europe, And U.K (RTTNews)
21.05.24	Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK (GlobeNewswire)
21.05.24	Teva Says Simlandi Injection Now Available In U.S. (RTTNews)
21.05.24	Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. (GlobeNewswire)
15.05.24	Alvotech S.A. Annual General Meeting to be held June 7, 2024 (GlobeNewswire)
13.05.24	Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) (GlobeNewswire)
02.05.24	Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 (GlobeNewswire)
30.04.24	Alvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For Quallent (RTTNews)
30.04.24	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) (GlobeNewswire)
24.04.24	Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) (GlobeNewswire)
19.04.24	Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) (GlobeNewswire)
17.04.24	Alvotech And Teva : FDA Approves Selarsdi Injection For Psoriasis And Psoriatic Arthritis (RTTNews)
16.04.24	Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) (GlobeNewswire)
03.04.24	Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 (GlobeNewswire)
22.03.24	Alvotech Announces Increase in Number of Own Shares (GlobeNewswire)
20.03.24	Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update (GlobeNewswire)
05.03.24	Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET (GlobeNewswire)
29.02.24	Alvotech Appoints Interim Chief Quality Officer (GlobeNewswire)
26.02.24	Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share (GlobeNewswire)
24.02.24	Alvotech And Teva Announce U.S. Approval Of SIMLANDI Injection (RTTNews)
24.02.24	Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® (GlobeNewswire)
15.02.24	Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) (GlobeNewswire)
05.02.24	Biotech High-Flyers That Just Hit 52-Week Highs (RTTNews)
31.01.24	Biotech Stocks Facing FDA Decision In February 2024 (RTTNews)
29.01.24	Alvotech Reports Positive Results For AVT03 Pharmacokinetic Study (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alvotech Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten